You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR SODIUM PHENYLBUTYRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for sodium phenylbutyrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002796 ↗ Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer Terminated National Cancer Institute (NCI) Phase 1/Phase 2 1997-05-01 Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the growth of the tumor. Combining more than one drug with interferon-gamma may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of giving fluorouracil together with phenylbutyrate, indomethacin, and interferon-gamma and to see how well it works in treating patients with stage IV colorectal cancer
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed Johns Hopkins University Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed National Center for Research Resources (NCRR) Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for sodium phenylbutyrate

Condition Name

Condition Name for sodium phenylbutyrate
Intervention Trials
Urea Cycle Disorders 6
Myelodysplastic Syndromes 3
Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for sodium phenylbutyrate
Intervention Trials
Urea Cycle Disorders, Inborn 9
Disease 7
Leukemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for sodium phenylbutyrate

Trials by Country

Trials by Country for sodium phenylbutyrate
Location Trials
United States 107
Canada 4
Italy 3
Spain 3
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for sodium phenylbutyrate
Location Trials
New York 13
Texas 12
Pennsylvania 9
Maryland 9
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for sodium phenylbutyrate

Clinical Trial Phase

Clinical Trial Phase for sodium phenylbutyrate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for sodium phenylbutyrate
Clinical Trial Phase Trials
Completed 27
Recruiting 5
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for sodium phenylbutyrate

Sponsor Name

Sponsor Name for sodium phenylbutyrate
Sponsor Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland 6
National Cancer Institute (NCI) 5
Sidney Kimmel Comprehensive Cancer Center 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for sodium phenylbutyrate
Sponsor Trials
Other 49
NIH 13
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.